LCA reports for Johnson & Johnson Innovative Medicine sponsored phase-2, 3, 4 clinical trials
Data files
Jan 31, 2025 version files 411.38 KB
-
28431754DIA4032_Diabetes.xlsx
46.11 KB
-
42756493BLC2002_Norse.xlsx
91.34 KB
-
54767414MMY3012_Columba.xlsx
87.58 KB
-
77242113PSO2001_Frontier.xlsx
72.30 KB
-
R092670PSY3016_Route_6.xlsx
47.93 KB
-
README.md
4.23 KB
-
VAC18193RSV3006_RSV.xlsx
61.91 KB
Abstract
Objective: To calculate the global warming potential, in carbon dioxide (CO2) equivalent emissions, from all in-scope activities involved in phase-1, 2, 3, and 4 clinical studies spanning multiple disease areas
Design: Retrospective analysis
Data source: Data collected by Johnson & Johnson Innovative Medicine during study conduct
Studies included: Johnson & Johnson Innovative Medicine sponsored 77242113PSO2001 (ClinicalTrials.gov: NCT05364554), 42756493BLC2002 (ClinicalTrials.gov: NCT03473743), 54767414MMY3012 (ClinicalTrials.gov: NCT03277105), VAC18193RSV3006 (ClinicalTrials.gov: NCT05070546), R092670PSY3016 (ClinicalTrials.gov: NCT04072575), and 28431754DIA4032 (ClinicalTrials.gov: NCT04288778) clinical studies conducted between 2018-2023
Main outcome: measure CO2 equivalents (CO2e) for in-scope clinical trial activities calculated according to Intergovernmental Panel on Climate Change (IPCC) 2021 impact assessment methodology.
README: Title of Dataset: LCA Reports for Johnson & Johnson Innovative Medicine Sponsored Phase-2, 3, 4 Clinical Trials
Dataset “54767414MMY3012 Columba.xlsx” represents the underlying data used in the performance of a peer-reviewed LCA on the Janssen-sponsored 54767414MMY3012 (ClinicalTrials.gov: NCT03277105) clinical study. The dataset includes both foreground and background data used to perform the LCA of the the clinical trial.
Dataset “77242113PSO2001 Frontier.xlsx” represents the underlying data used in the performance of a peer-reviewed LCA on the Janssen-sponsored 77242113PSO2001 (ClinicalTrials.gov: NCT05364554) clinical study. The dataset includes both foreground and background data used to perform the LCA of the the clinical trial.
Dataset “42756493BLC2002 Norse.xlsx” represents the underlying data used in the performance of a peer-reviewed LCA on the Janssen-sponsored 42756493BLC2002 (ClinicalTrials.gov: NCT03473743) clinical study. The dataset includes both foreground and background data used to perform the LCA of the the clinical trial.
Dataset “VAC18193RSV3006 RSV.xlsx” represents the underlying data used in the performance of a peer-reviewed LCA on the Janssen-sponsored VAC18193RSV3006 (ClinicalTrials.gov: NCT05070546) clinical study. The dataset includes both foreground and background data used to perform the LCA of the the clinical trial.
Dataset “R092670PSY3016 Route 6.xlsx” represents the underlying data used in the performance of a peer-reviewed LCA on the Janssen-sponsored R092670PSY3016 (ClinicalTrials.gov: NCT04072575) clinical study. The dataset includes both foreground and background data used to perform the LCA of the the clinical trial.
Dataset “28431754DIA4032 Diabetes.xlsx” represents the underlying data used in the performance of a peer-reviewed LCA on the Janssen-sponsored 28431754DIA4032 (ClinicalTrials.gov: NCT04288778) clinical study. The dataset includes both foreground and background data used to perform the LCA of the the clinical trial.
Description of the Data and file structure
The foreground and background data is grouped by element of the clinical trial and structured in separate tabs for each group. Data is organized in tabular format. Regarding the background data, for each unit (used to extend the foreground data into life cycle perspective), additional information is provided, i.e., the source, whether Ecoinvent v3.8 and Agribalyse 3.0 LCI databases, is noted as well as it’s reference year, geography, source, and proxy (if relevant).
"Foreground" tab containing all foreground data. This tab contains the following foreground data tables:
- Table A.1: Input - output tables – data collection method key
- Table A.2: Foreground data – patient travel
- Table A.3: Foreground data – drug product
- Table A.4: Foreground data – local consumables
- Table A.5: Foreground data – testing kits
- Table A.6: Foreground data – samples
- Table A.7: Foreground data – trial meetings
- Table A.8: Foreground data – trial site impacts and procedures
- Table A.9: Foreground data – clinical trial management
"Background" tab containing all background data. This tab contains the following background data tables:
- A.10: Background datasets used in the study
Sharing/access Information
Links to other publicly accessible locations of the data: N/A
Was data derived from another source?
If yes, list source(s): Background data was sourced from the Ecoinvent v3.9 and Agribalyse 3.0 LCI databases. Ecoinvent is one of the largest repositories of environmental impact factors and is commonly used by LCA practitioners. A license fee is required to access Ecoinvent and we are prohibited under the license agreement from publicly disclosing the exact impact factor values we used. However, where Ecoinvent proxy values are used, we identify the source (Ecoinvent 3.9), the exact name of the environmental impact factor as described in the Ecoinvent database, the year of the reference value, and the geographic context (where applicable), so that anyone with an Ecoinvent license can locate the exact values we used in our calculations and replicate our work.
Methods
Retrospective analysis of recently completed clinical studies leveraging internal data held by Johnson & Johnson Innovative Medicine. The LCAs were conducted under a dynamic and iterative approach in accordance with ISO 14040/44 standards, and peer reviewed by a third party.